TRIMPEX
LOE ApproachingNDAORALTABLET
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIMPEX is an oral small-molecule tablet approved by Roche in 1980 with an unknown mechanism of action and indication profile. Specific therapeutic uses and patient populations cannot be confirmed from available data. The drug is a legacy NDA product nearing loss of exclusivity.
LOE Approaching
Low commercial momentum with minimal linked job opportunities; team is likely in maintenance or transition mode ahead of generic entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIMPEX offers limited career growth opportunities with zero linked job postings. Working on this product means focusing on defensive commercial strategies, generic erosion mitigation, and compliance rather than innovative development or market expansion.
Brand Manager (Legacy)Regulatory Affairs Specialist
Worked on TRIMPEX at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.